Neurofeedback reduces chemo-induced nerve damage
A type of functional brain training known as neurofeedback shows promise in reducing symptoms of chemotherapy-induced nerve damage, or neuropathy, in cancer survivors, according to a study by researchers at The University of Texas MD Anderson Cancer Center. The study is the largest, to date, to determine the benefits of neurofeedback in cancer survivors.
Chronic chemotherapy-induced peripheral neuropathy (CIPN) is caused...
The cancer leaders of tomorrow
While many times, the achievements of senior faculty members receive the greatest attention, MD Anderson is also taking steps to highlight...
Building a personalized approach to cancer therapy
In 2011, the MD Anderson Cancer Center received a $150 million gift — the largest in the history of the institution — from the Khalifa Bin...
Researchers find new potential drug target in triple-negative breast cancer
The goal of harnessing the power of one's immune system to target and kill cancer cells just got a boost. New research from MD Anderson has yielded promising insights into a protein known as PDL1, which was found to be expressed in 20% of triple negative breast tumors.
Triple-negative disease is more aggressive than other types of breast cancer and is not fueled by female hormones estrogen and progesterone or by the cancer growth-promoting...
Advanced form of proton therapy offers benefits for head, neck cancer patients
Oral cancer patients with tumors at the back of the throat are half as likely to require a feeding tube when treated with intensity modulated...
Eating and swallowing exercises during treatment benefit cancer patients later
New MD Anderson research published in JAMA Otolaryngology Head and Neck Surgery indicates that oral exercises help patients maintain their...
Research uncovers tie between two cancer-promoters in breast cancer
MD Anderson scientists have found a molecular signaling pathway that connects two known contributors to cancer cell growth and survival. They...
Melanoma faculty contribute to Nature Medicine's 2012 top advances
By Leslie Loddeke, Publications Coordinator, Melanoma Medical Oncology Department
MD Anderson Melanoma Medical Oncology...
Institute of Medicine elects Lynda Chin to membership
Lynda Chin, M.D., professor and chair of MD Anderson's Department of Genomic Medicine and scientific director of the Institute for Applied...
MD Anderson Experts Review Leukemia, Lymphoma, Multiple Myeloma Progress
Andrew Schorr is a pioneer in health communications and patient education and, along the way, became a patient himself. Andrew was diagnosed...